The comet test is a reported method for measuring DNA damage in individual mammalian cells. In the present report, the ability of this test to detect multidrug resistance (MDR) was evaluated. For this purpose, two human leukemia, well-characterized parental cell lines, HL60 and CEM, and their derived multidrug-resistant cells, HL60/DNR and CEM/VBL, were cultured with or without different anti-cancer agents. To evaluate the comet test, two DNA-damaging agents were used: daunorubicin (DNR), which is involved in MDR, and ambamustine (AMBA), which is independent from MDR. Moreover, in order to evaluate the specificity of the comet test, the activity of vinblastine (VBL), an MDR-related, DNA-independent anti-cancer drug, was also tested. Finally, the specificity of the comet test in detecting MDR was confirmed by culturing parental or resistant cells with DNR with or without the revertant agent verapamil (VER). Results confirm that the comet test is able to predict cellular chemoresistance when DNA damaging agents are tested. Finally, experiments on the role of the comet test in evaluating certain aspects of DNA repair are discussed.
Introduction
De novo or, more often, acquired resistance to cytotoxic agents is extremely frequent in human cancer and it appears to be the major obstacle to the success of cancer chemotherapy. Among many possible mechanisms of drug resistance, cellular expression of typical and atypical multidrug resistance (MDR) has been shown to be related to the prognosis of several hematological malignancies. A large body of evidence has been accumulated in more than 10 years, suggesting that the most frequent form of MDR is based upon the ability of cells to express a membrane glycoprotein (Pglycoprotein or P-170) 1 which acts as an efflux pump for several unrelated anti-cancer drugs (for a review see Ref 2) . In spite of good evidence suggesting that the expression of the mdr-1 gene, codifying for P-170, is related to chemoresistance, at least in some hematological malignancies such as acute myeloid leukemia and multiple myeloma, it is evident that this does not completely explain the complex phenomenon of multidrug resistance. In fact, atypical MDR has been related to altered topoisomerase expression, 3 expression of multidrug resistance protein (MRP) 4 and increased lung resistance-related protein (LRP). 5 It is probable that several other resistance mechanisms exist. Besides evaluating the cells for their expression of MDR-related mechanisms, we decided to verify whether the comet test, which is usually employed to evaluate DNA damage and repair, could be useful for testing chemoresistance in cell lines.
The single cell gel electrophoresis (SCGE) assay, also known as the comet test, is a rapid, simple, sensitive, visual technique for measuring and analyzing DNA breakage in individual mammalian cells. [6] [7] [8] [9] [10] Single-strand breaks (SSBs) are commonly measured by procedures that include treatment at high pH, or alkaline unwinding, alkaline elution and alkaline sucrose sedimentation. The comet test is an adaptation of other methods such as nucleoid sedimentation and the halo assay, and the introduction of alkaline conditions 7 makes it possible to establish the dose relationship with single-strand breakage induction and repair.
It is expected that chemoresistant cells exposed to optimal drug concentrations will show less DNA damage than parental ones, or in turn, that the drug concentration which induces DNA damage in 50% of cells will be higher in resistant cells than in parental ones.
To confirm this hypothesis and to study the possible application of the comet test in evaluating drug resistance, cells were cultured in the presence of anti-cancer drugs acting by different mechanisms. Cells were treated with the anthracycline daunorubicin (DNR) or the alkylating agent ambamustine (AMBA), both capable of inducing DNA damage by intercalating or alkylating mechanisms, respectively. As DNR is involved in MDR, whereas AMBA is independent from MDR, the comparison between the activities of these two drugs in parental and resistant cell lines was likely to make it possible to evaluate the possible role of the comet test in studying MDR. Furthermore, cells were cultured with vinblastine (VBL), an MDR-related antiblastic drug acting on the microtubular system without damaging DNA. Besides confirming the specificity of the comet test to evaluate DNA damage, this latter assay might indicate possible limits of the comet test in evaluating chemoresistance.
MDR may be fully or partially reverted by several agents, including the Ca ++ antagonist verapamil (VER). Addition of VER to cells cultured with DNR, may allow us to confirm the possible use of the comet test to evaluate MDR.
Finally, it has been reported that cell populations exposed to agents inducing comets may repair their DNA damage and this may be appreciated by repeating the test at intervals after post-exposure incubation. Thus the comet test could be useful in evaluating DNA damage and DNA repair activity.
Materials and methods

Cell culture and drug treatment
Four different human cell lines were used in these experiments: the human leukemia HL60 cell line, its DNR-resistant counterpart HL60/DNR (kindly supplied by Prof JP Marie, Hotel Dieu, Paris, France), the human T cell lymphoblastic leukemia cell line CEM, and its VBL-resistant derivative CEM/VBL 100 (kindly supplied by Dott M Cianfriglia, Ist Sup. di Sanità, Roma, Italy).
Drug resistance of both HL60/DNR and CEM/VBL was originally characterized by evaluating resistance to several antiblastic agents. The MDR phenotype was characterized using monoclonal antibodies directed against P-170. 11, 12 In our laboratory the MDR phenotype was confirmed by several tests. The resistance index (RI = inhibiting dose (ID 50 ) of the resistant cell line/ID 50 of the parental cell line) of HL60/DNR to DNR was 200, whereas the RI of CEM/VBL to VBL was 137 and to DNR was 26.6. The RI to the MDR-unrelated alkylating agent AMBA was approximately 1 for both cell lines. Furthermore, reactivity of resistant lines to monoclonal antibodies JSB-1 13 and MM 4.17 14 which detect an internal and an extracellular domain of P-170, respectively, was proved by cytofluorimetry (data not shown). Finally, expression of the mdr-1 gene was shown by RT-PCR, using a specific primer to amplify mdr-1 mRNA. 15 All cell lines were cultured at 37°C in a humidified atmosphere containing 5% CO 2 , in RPMI 1640 liquid medium with 10% fetal calf serum, L-glutamine 2 mM, and gentamycin 100 g/ml (all components were purchased from Gibco BRL, Milan, Italy). Furthermore, DNR (0.2 g/ml) (Pharmacia, Milan, Italy) was added to the HL60/DNR culture medium while VBL (0.1 g/ml) (Lilly Italia S.p.a., Florence, Italy) was added to the CEM/VBL culture medium.
Treatment of cells suspended in RPMI 1640 at a density of 1 × 10 6 cells/ml, was carried out at 37°C, for 1 h, in the presence of different concentrations of the tested chemical agents. Untreated controls were processed in parallel. Viability was evaluated by trypan blue exclusion.
CEM and CEM/VBL were treated with VBL (0.2 g/ml or 1 g/ml) or with DNR (0.1 g/ml to 10 g/ml).
HL60 and HL60/DNR were treated with DNR (0.1 g/ml to 20 g/ml) or AMBA (a kind gift from Knoll, Milan, Italy) (0.2 g/ml to 10 g/ml) while HL60/DNR were treated with DNR 0.1 g/ml in combination with VER (Knoll) 2.5 M.
After treatment, cell viability was checked and the comet test was performed only with a viability у80%. Cells were spun down and re-suspended either in 0.7% agarose solution for the comet assay or in culture medium (drug-free) to evaluate cell proliferation.
To examine repair of DNA damage by HL60 and HL60/DNR, cells were cultured with DNR concentrations inducing 50% of comets, washed and incubated at the concentration of 5 × 10 5 /ml at 37°C in the culture medium. Samples were taken after 24 and 72 h for analysis by the comet test.
Single cell gel electrophoresis (comet assay)
The comet test was performed in the dark under alkaline conditions as reported by Singh et al 7 with minor modifications. After drug treatment, 2 × 10 5 cells were suspended in 85 l 0.7% low melting-point agarose solution in Ca 2+ -Mg 2+ -free PBS, at 37°C and pipetted on to roughened frosted slides precoated with a layer (100 l) of 0.5% normal melting-point agarose (Sigma-Aldrich, Milan, Italy). The agarose was allowed to set at 4°C for 10 min and after the application of a third layer (100 l) of 0.7% low melting-point agarose solution, the slides were immersed in the lysis solution (1% sodium sarcosinate, 2.5 M NaCl, 100 mM Na 2 EDTA, 10 mM Tris-HCl, NaOH to pH 10, 1% Triton X-100 and 10% DMSO; all components were purchased from Sigma-Aldrich) at 4°C for 1 h to remove cellular proteins. The slides were then placed in a sub-cell electrophoresis unit (Biorad, Milan, Italy), allowing the DNA to unwind for 20 min in the electrophoresis buffer (1 mM Na 2 EDTA, 300 mM NaOH, pH 12), followed by electrophoresis for 20 min at 30 V, 300 mA. Then the slides were neutralized with 0.4 M Tris-HCl (pH 7.5) and stained with 100 l of ethidium bromide (Sigma) (20 g/ml).
The slides were placed in a humidified air-tight container at 4°C to prevent drying of the gel, and were analyzed the day after.
Slides were examined at magnification × 1000 by a fluorescence microscope using a calibrated scale in the ocular. Width of the nucleus and migration extent of DNA fragments (whole comet image) of 50 cells per slide were determined by two independent observers. Two parallel tests were performed per trial for a total of 100 cells and the mean, median of tail length distribution and percentage of comets were calculated. Each complete experiment was repeated two to four times.
As the distribution of tail length was Gaussian, we assume the critical length which defines a comet as the length over the 95th percentile of tail length distribution among nontreated controls. Significance of differences was assayed by the Mann-Whitney U test.
Assessment of drug toxicity
After drug treatment, cells (2 × 10 5 /well) were plated in 96-well plates in the presence of 2 Ci of 3 H-thymidine (Amersham Italia S.r.l., Milan, Italy) per well. After 24 h, cells were harvested and transferred to filters. Dried filters were then transferred into vials containing scintillation fluid and the radioactivity was determined using a ␤-counter and expressed as counts per minute (c.p.m.). These experiments were used to evaluate the inhibition index.
Results
Independently of the cell line evaluated, the median length of comets in untreated cells was 30.8 ± 2.7 m, the mean length was 30.3 ± 2.3 m and the 95th percentile ranged from 35 m to 45 m. In each experiment, the median was close to the mean and does not add any extra information and consequently is not reported.
In experiments performed to evaluate DNR activity on HL60 (IC 50 0.1 g/ml) and HL60/DNR (IC 50 20 g/ml), the tail length and the percentage of comets were found to increase with the dose of the drug employed; the comets length ranged from 32.0 ± 1.8 m to 68.4 ± 4.8 m (Figure 1 ). It should be noted that the parental and resistant cell lines were differently responsive to treatment with DNR: the concentration of DNR that induced comets in 50% of cells was 20 times higher for HL60/DNR resistant cells (10 g/ml) than for HL60 cells (0.5 g/ml). No difference was found when cells were treated with the alkylating agent AMBA, which induced the same frequencies of comets in these two cell lines (Figure 2) . AMBA induced comparable cell growth inhibition in both parental and resistant cell lines, the IC 50 being 10 g/ml for both cell lines. DNR (0.1 g/ml) added to HL60/DNR cell cultures in the presence of 2.5 M VER induced 32 ± 2.8% of comets, whereas the same DNR concentration without VER does not induce any comets in the same cell line. It should be noted that 0.1 g/ml DNR is lower than the concentration used for maintaining resistant cells in culture. The percentage of com-
Figure 1
Daunorubicin activity in HL60 and HL60/DNR cell lines. Tail length and percentage of comets were related to the dose of drug employed. The critical length which defines a comet was calculated as the length over the 95th percentile of tail length distribution among non-treated controls. Comets % (a) and means of tail length distribution (b) were calculated on 100 cells and experiments were repeated two to four times. (s) Means that the comet test was not performed because the cell viability after culturing with the concentrations reported was well below the accepted threshold of 80% (Ͻ 5%). ets found after culturing resistant cells with the reported concentrations of DNR and VER is even higher than that induced in parental cells with the same dose of the anthracycline (Figure 3) .
No comets were induced by 0.2 or 1 g/ml VBL in CEM (IC 50 0.73 ng/ml) and CEM/VBL cells (IC 50 100 ng/ml). VBL is a drug known to interact with tubulin, but not with DNA.
Conversely, DNR concentrations able to induce comets in CEM (IC 50 0.15 ng/ml) and CEM/VBL (IC 50 4 ng/ml) cells were significantly different: the dose of DNR that induced comets in 70% of resistant cells was 33 times higher than that inducing comets in 70% of parental cells (Figure 4 ).
HL60 and HL60/DNR were treated with DNR doses able to induce a known amount of DNA damage (0.5 g/ml DNR induced 50% of comets (DC 50 ) in the HL60 cell line whereas the DC 50 of the HL60/DNR cell line was 10 g/ml DNR) and were then allowed to repair for the following 72 h: the HL60 parental cell line largely restitutes high molecular DNA whereas the percentage of comets was reduced in HL60 by 47% 72 h after treatment. Conversely, comets detected at the same time with DNR 10 g/ml in the HL60/DNR-resistant cell line did not show any reduction ( Figure 5 ). In both cases,
Figure 2
Ambamustine activity in HL60 and HL60/DNR cell lines. Tail length and percentage of comets were related to the dose of drug employed. The critical length which defines a comet was calculated as the length over the 95th percentile of tail length distribution among non-treated controls. Comets % (a) and means of tail length distribution (b) were calculated on 100 cells and experiments were repeated two to four times.
Figure 3
Revertant effect of verapamil in HL60/DNR cell line. Daunorubicin (0.1 g/ml) with verapamil (2.5 M) induce comets in the HL60/DNR cell line, whereas the same DNR concentration without VER induce comets in only the parental HL60 cell line. Percentage of comets in HL60/DNR treated with DNR (0.1 g/ml) without VER does not differ from controls.
cell viability is higher than 80% both after 1, 24 and 72 h, confirming that variations in percentages of comets do not depend on the late toxicity of the antiblastic agent.
Discussion
Methods used to detect MDR are immunological, functional and molecular. It has recently been confirmed that these tests are not fully suitable for ex vivo studies and their reproducibility among independent laboratories is largely unacceptable. 16 For these reasons, we assayed whether the comet test is able to evaluate the expression of chemoresistance in known, well-characterized, parental, strongly resistant human cell lines. Three anti-cancer drugs belonging to different families were used in this study: (1) DNR, an MDRrelated anthracycline acting on DNA by three major mechanisms: first, it may intercalate between base pairs of DNA, thus disrupting DNA replication and RNA transcription; second, anthracyclines can produce single-and doublestranded DNA scission and a third mechanism capable of generating DNA breaks is the creation of free radicals. 17 (2) AMBA, a new synthetic bifunctional alkylating agent similar to melphalan; the anti-tumor effect of AMBA is based on base alkylation and interstrand cross linkage of DNA. 18 DNA alkylation has several effects including depurination, doubleand single-stranded breaks; alkylating agents do not interfere with MDR.
2 (3) VBL, which binds to the protein tubulin, preventing protein polymerisation and thus blocking the cell cycle in the metaphase. Vinca alkaloids are involved in MDR. 17 Drug concentrations were selected for each cell line on the basis of the IC 50 .
The results clearly show that the comet test is able to detect drug-induced DNA damage: increases in the percentage of comets and length of the tail were found in all cell lines examined by increasing DNR or AMBA drug concentrations Daunorubicin activity in CEM and CEM/VBL cell lines. Tail length and percentage of comets were related to the dose of DNR employed. The critical length which defines a comet was calculated as the length over the 95th percentile of tail length distribution among non-treated controls. Comets % (a) and means of tail length distribution (b) were calculated on 100 cells and experiments were repeated two to four times. in the range evaluated. AMBA does not interfere with MDR and its RI was approximately 1. As expected, it induced a similar percentage of comets in both parental and resistant HL60. Conversely, DNR activity was completely different for resistant and parental cells. Whereas a significant increase of comets was found in both CEM and HL60 at 0.1 g/ml DNR (P Ͻ 0.01), the anthracycline induced comets in the respective resistant cell lines only at five to 10 times higher concentrations. A comparison of the DNR concentrations that induced 50% of comets both in parental and resistant cells confirmed a close relationship between the results of the comet test and the MDR phenotype. A possible limitation of the comet test is related to its relative inefficiency, as it works with cell populations showing a viability Ͼ80% and thus with cells treated with strongly toxic drug concentrations. These results confirm that the comet test may be useful in evaluating MDR expression. An obvious limitation lies in the fact that this test is able to identify DNA damage but will not detect the activity of drugs not directed at nucleic acids. This is the case, for instance, with vinca alkaloids, which are substrates for MDR. In fact, in our experiments, it was not possible to detect any difference between treated or untreated parental or resistant cells when VBL was evaluated. Thus, the ability Repair test. Percentage of comets found after treatment of HL60 and HL60/DNR cell lines with DNR at DC 50 (DC 50 ) is the DNR concentration able to induce comets in 50% of cells; DC 50 was 0.5 g/ml for the HL60 cell line and 10 g/ml for the HL60/DNR cell line). The test was carried out 1 h after treatment and repeated at 24 h and at 72 h, after removing the drug. After 72 h, restitution of highmolecular weight DNA was found in the HL60 cell line (reduction of comets % by about half). No 'repair' was found in HL60/DNR for the dose used which led to the same percentage of comets at 1 h. of the comet test to predict the MDR phenotype or drug involvement in MDR is restricted to the use of DNA-damaging drugs.
The specificity of the comet test used to assay chemoresistance was confirmed by evaluating the activity of the revertant agent, verapamil. This drug is a Ca ++ antagonist able to compete with antiblastic agents for P-glycoprotein binding, thus preventing MDR-related detoxification.
Moreover, this test makes it possible to detect MDR in a functional way after a very short culture time (1 h).
When cells are cultured for 24-72 h both in the presence of DNR and after repeated washing, the test makes it possible to evaluate the repair activity of DNA damage.
This experiment shows that after culturing HL60 parental and HL60 resistant cells with a DNR concentration able to induce 50% of comets, HL60, but not HL60/DNR, largely restitutes high molecular DNA. Of course, restitution of highmolecular weight DNA during post-treatment incubation does not mean that this repair is faithful but the results reported could stimulate an evaluation of the role of certain complex repair mechanisms, such as those involved in singlestrand breaks repair, in drug resistance.
Finally, a comparison of the comet test with previously reported methods to evaluate MDR is not easy. Of course, the comet test cannot substitute for methods able to detect proteins related to chemoresistance or gene expression. Evaluation of the MDR phenotype may not fully predict cell chemoresistance and additional functional tests are requested. Expulsion of fluorescent MDR substrates (ie anthracyclines or rhodamine) gives an indication of the function of P-glycoprotein, but is not directly related to the effects of anticancer agents. Lastly, cytotoxicity tests may be influenced by in vitro culturing conditions and may not correlate to the in vivo toxicity. It appears interesting to underline that the comet test evaluates cell susceptibility to DNA damage, thus making it possible to study the action of several antiblastic agents on their substrate. In order to fully clarify the role of the comet test in evaluating MDR, we are planning to study comet parameters in MDR-characterized cells from leukemia patients before and after chemotherapy.
